Online inquiry

IVTScrip™ mRNA-Anti-TNFRSF18, MEDI-1873(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ11205MR)

This product GTTS-WQ11205MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 0 & N1-Methylpseudo-UTP. It ecodes the monoclonal antibody that targets TNFRSF18 gene. The antibody can be applied in Solid tumors research.
Specifications
Product type mRNA
Modified bases N1-Methylpseudo-UTP
5' Cap Cap 0
Species Homo sapiens
RefSeq NM_004195.3
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 8784
UniProt ID Q9Y5U5
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-TNFRSF18, MEDI-1873(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) (GTTS-WQ11205MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ357MR IVTScrip™ mRNA-Anti-ALB&IL6R, 20A11-9mer-ALB11(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA 20A11-9mer-ALB11
GTTS-WQ1362MR IVTScrip™ mRNA-Anti-IL12B, ABT-874(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA ABT-874
GTTS-WQ12174MR IVTScrip™ mRNA-Anti-MSLN, MORAb-009(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA MORAb-009
GTTS-WQ11110MR IVTScrip™ mRNA-Anti-TNFRSF8, MDX-060(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA MDX-060
GTTS-WQ11547MR IVTScrip™ mRNA-Anti-CD3E, MGA031(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA MGA031
GTTS-WQ11720MR IVTScrip™ mRNA-Anti-IL13, MILR1444A(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA MILR1444A
GTTS-WQ5608MR IVTScrip™ mRNA-Anti-KDR, CDP791(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA CDP791
GTTS-WQ3435MR IVTScrip™ mRNA-Anti-HGF, AV-299(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA AV-299
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW